Dose-dependent down-modulation of VLA-4 expression on pDCs in vitro after 6 days of culture of PBMCs from healthy controls with 3 different doses of natalizumab (NTZ)—22 (×1/5), 110 (1×), and 550 µg/mL (5×), respectively—and antigen-specific stimulus (PPD, 50 IU/mL).

<p>The case shown is representative of 3 independent experiments. Isotypic IgG4 control is marked in red. These results were not reproduced in the MS patients tested (n = 3).